RxDoctor Payments Data

Heather Joslin

Family · Eastover, NCNPI 1669941928

Payments from drug & device makers

$6,097in general payments, 2019–2025

Across 318 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$712
  • Novo Nordisk$376
  • Pfizer$258
  • GSK$195
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$6,02299%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,097 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$36,707
Medicare patients
166
Services billed
566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$93,934
MounjaroTirzepatide68$75,545
TrulicityDulaglutide37$56,106
EliquisApixaban67$51,377
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$51,061
JanuviaSitagliptin Phosphate36$41,981
FarxigaDapagliflozin Propanediol39$40,727
ZenpepLipase/Protease/Amylase11$40,719
Breztri AerosphereBudesonide/Glycopyr/Formoterol53$39,074
LinzessLinaclotide36$27,048
JardianceEmpagliflozin15$24,659
JanumetSitagliptin Phos/Metformin Hcl13$11,987
EntrestoSacubitril/Valsartan15$10,337
AirsupraAlbuterol Sulfate/Budesonide14$10,039
Emgality PenGalcanezumab-Gnlm13$8,910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$712$131,651105 claims
Novo NordiskOzempic$376$93,93482 claims
AstraZenecaFarxiga, Breztri Aerosphere, Airsupra$1,629$89,840106 claims
PfizerEliquis$258$51,37767 claims
GSKTrelegy Ellipta$195$51,06151 claims
Aimmune Therapeutics, Inc.Zenpep$15$40,71911 claims
AbbVieLinzess$1,809$27,04836 claims
Boehringer IngelheimJardiance$16$24,65915 claims
Scilex Pharmaceuticals Inc.Colchicine$20$1,28924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Eastover

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →